论文部分内容阅读
国产氟罗沙星静滴治疗１０２名呼吸道、泌尿道、消化道和皮肤软组织感染患者，总的临床有效率为９５．１０％（９７／１０２），细菌清除率为９４．６８％（８９／９４）。不良反应轻微，不影响继续治疗，不良反应发生率为８．８２％。同时以氧氟沙星为对照药，在呼吸道和泌尿道感染中进行了随机对照实验，氟罗沙星组６２例，氧氟沙星组６０例，两组的临床和细菌学疗效及不良反应发生率相似。并对１２５株临床分离菌测定了氟罗沙星和氧氟沙星的ＭＩＣ，结果显示氟罗沙星对肠杆菌科细菌和葡萄球菌属具有高度的抗菌活性，对假单胞菌也有良好的活性。
The total clinical effective rate was 95.10% (97/102) and the bacterial clearance rate was 94.68% (89/94) in domestic 102 patients treated with fleroxacin intravenously in 102 patients with respiratory tract, urinary tract, digestive tract and skin and soft tissue infections. . Minor adverse reactions, does not affect the continued treatment, the incidence of adverse reactions was 8.82%. At the same time, ofloxacin as a control drug, respiratory tract and urinary tract infections in a randomized controlled trials, fleroxacin 62 cases, ofloxacin 60 cases, the two groups of clinical and bacteriological effects and adverse reactions similar. The MICs of fleroxacin and ofloxacin were measured in 125 clinical isolates. The results showed that fleroxacin had high antibacterial activity against Enterobacteriaceae and Staphylococcus, and also had good activity against Pseudomonas.